Vanderbilt Cardio-Oncology program is offering 1 year or 2 year clinical and research fellowships to highly motivated individuals. Our program includes clinical training, didactic teaching and a research experience. The primary goal of the training program is to prepare trainees to become outstanding academic physicians in cardio-oncology, involved in research, education and clinical activities and future leaders in this young field.
The Vanderbilt cardio-oncology fellowship is a Vanderbilt Graduate Medical Education (GME) approved fellowship that provides a structured curriculum including weekly didactic sessions, clinical rotations, and cardio-oncology based research experience. Fellows rotate through the outpatient cardio-oncology and amyloid clinics as well as dedicated oncology clinics, which will expose them to the various aspects of oncology and oncology care. These dedicated oncology clinics will include breast cancer, prostate cancer, melanoma, leukemia/lymphoma, transplant, gastrointestinal, genitourinary, and radiation oncology clinics, as well as the early drug development and survivorship oncology clinical programs. This broad clinical experience is made possible by an integrated cardiovascular center and access to world-class academic faculty in oncology and cardiology. Close collaboration with various departments at Vanderbilt University allows for integration with other aspects of the cardiovascular division including heart failure, vascular medicine, cardiac imaging, arrhythmia, autonomic dysfunction and genetics programs.
Importantly, the cardio-oncology fellowship can be tailored to each individual’s training needs. Because of the broad expertise of the Vanderbilt cardiovascular division, the cardio-oncology fellowship can be combined with specific areas of interest in cardiology including imaging, heart failure, interventional cardiology, basic research, clinical/translational research and clinical trials. Applicants who are interested in basic/clinical research may be supported by the longstanding T32 NIH. Cardio-oncology collaborates closely with other graduate schools at Vanderbilt to allow for opportunities for graduate degrees including Master of Public Health or Master of Science and Clinical Investigation (MSCI).
Because cardio-oncology is a new field, an important emphasis of the Vanderbilt cardio-oncology training is innovation and research. Research begins with the development of a focused plan during the early phase of fellowship. The trainee research goals can be integrated into the many ongoing basic, translational, and clinical projects within the group. Vanderbilt cardio-oncology program is also closely aligned with other programs in the university, including Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC: https://medschool.vanderbilt.edu/vtracc/) and Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART: http://www.mc.vanderbilt.edu/root/vumc.php?site=vancart).
Interested individuals should send their curriculum vitae to Dr. Javid Moslehi, Director, Vanderbilt Cardio-Oncology program, at firstname.lastname@example.org. All interested applicants need to have completed cardiology fellowships to be considered eligible. However, individuals with exceptional research backgrounds will also be considered.
Vanderbilt Cardio-Oncology Fellows (2018-2019)
Joe-Elie Salem, MD, PhD
obtained his medical degree, medical residency and cardiovascular medicine training at Rene Descartes (Paris V) and Pierre and Marie Curie University (Paris VI) at University of Paris (Sorbonne), with additional diplomas in cardiovascular imaging (echocardiography, CT and MRI). During this time, he also completed a PhD thesis at Sorbonne University in clinical pharmacology focused on the efficacy, sources of variability, and occurrence of adverse effects of cardiovascular drugs. He was particularly interested in cardiovascular pharmacology, heart failure and drug-induced arrhythmias. His previous research focus is on the development of new tools to predict deleterious drug effects on cardiac repolarization (i.e., drug-induced long QT syndrome). More recently, he was Assistant Professor of Pharmacology at the Clinical Investigation Center (CIC) at Hopitaux de Paris and Pierre and Marie Curie University (Sorbonne). This experience led him to conceive, participate and assist in the coordination of numerous translational research programs and clinical trials, mainly in the field of cardio-metabolism and pharmacology. His training in cardio-oncology at Vanderbilt in hopes of later further taking his acquired skills to Sorbonne University. He was attracted to Vanderbilt because of the cutting edge medicine in cardio-oncology and precision medicine and was awarded grants from INSERM and AHA for the Vanderbilt fellowship. In the fall of 2018, Dr. Salem will return to France where he will be associate professor of cardiology and pharmacology at Sorbonne university. He will maintain an adjunct professorship at Vanderbilt.
Weijuan Li, MD, MS
is currently a third-year general cardiology fellow at Vanderbilt pursing a cardio-oncology sub-fellowship. She obtained her medical degree at Peking Union Medical College, Beijing, China and her master’s degree in biomedical sciences at UCSF, San Francisco, California. During her training at UCSF, her research focused on prostate cancer chemotherapy resistance mechanisms. She completed her internship and internal medicine residency training at Albert Einstein College of Medicine/Jacobi Medical Center. Her research projects during residency focused on hematological malignancies and investigating cell-signaling pathway targeted therapies. After seeing patients suffered from cardiovascular toxicities from their cancer treatments, she developed interest in cardio-oncology in her second year of residency. Her work, which included cardiovascular toxicities associated with tyrosine kinase inhibitors, cardiovascular and thromboembolic complications associated with novel multiple myeloma treatments, was published in highly ranked journals (JACC
, JAMA Oncology
) and now are well cited. Her current project is to investigate how cardiovascular co-morbidities can affect outcomes in patients with breast cancer by using large dataset. Her goal is to establish a cardio-oncology program in community setting and provide great cardiovascular care for cancer patients during their cancer treatment and survivorship.
Wouter Meijers, MD, PhD
obtained his medical degree at Maastricht University, the Netherlands, after which he started his PhD training at the Experimental Cardiology department of the University Medical Center Groningen, the Netherlands. He investigated heart failure biology and the role of biomarkers, with a special interest in galectin-3 and natriuretic peptides in both clinical and pre-clinical studies. During the last years of his PhD trajectory Wouter became specifically interested in the field of cardio-oncology. His most recent research in this field was partially funded by the Netherlands Heart Institute who granted him a Young Talent award. He presented his research at various international congresses and is currently fellow of the Heart Failure Association of the European Society of Cardiology and has a position in the study group on biomarkers coordinated by prof. Mueller. Wouter is currently a cardiology fellow at the University Medical Center Groningen, the Netherlands. He will temporarily interrupt his residency to pursue his research ambition at Vanderbilt University Medical Center. His goal is to expand a pre-clinical and clinical frontier in cardio-oncology in the Netherlands. The Vanderbilt Cardio-Oncology Fellowship will provide a strong scientific foundation, which he believes will allow him to succeed as a physician-scientist. The successfully obtained Netherlands Heart Institute fellowship grant enables him to conduct this research abroad for one year.
Vanderbilt Cardio-Oncology Fellowship - Alumni
Nirmanmoh Bhatia, MD – 2016-2017
Wendy Bottinor, MD – 2017-2018
Kristopher Swiger, MD – 2017-2018